As a result of this ruling, MNTA/NVS and MYL can launch generic Copaxone in May 2014 (instead of having to wait until Sep 2015), pending FDA approval, of course.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”